AstraZeneca Advances Hematology and Cell Therapy Ambitions with Largest-Ever ASH Presence

AstraZeneca is showcasing its hematology and cell therapy ambitions at the 67th American Society of Hematology Annual Meeting and Exposition. The company is presenting new data from its pipeline and portfolio, including preliminary results from the TrAVeRse Phase II trial evaluating CALQUENCE in treatment-naive MCL patients, exploratory analyses from the AMPLIFY Phase III trial in first-line chronic lymphocytic leukemia, and sub-analysis of the ALPHA Phase III trial evaluating VOYDEYA in paroxysmal nocturnal hemoglobinuria.